AIC, a division of AIS Healthcare, now offers YIMMUGO®, manufactured by Kedrion Biopharma, for the treatment of primary humoral immunodeficiency in patients 2 years of age and older.
Efgartigimod demonstrated superior efficacy over IVIG in improving MG-ADL and QMG scores in myasthenia gravis patients. Patients treated with efgartigimod experienced faster symptom improvement and ...
Kelley L. Julian, PharmD, BCOP, discusses optimizing myeloma care, addressing barriers in access to intravenous ...
Valley mother diagnosed with rare condition gives birth to baby boy after ‘1-in-a-million’ pregnancy
Bendu Kiazolu's long battle with fertility issues led to an innovative treatment during a "one-in-a-million" pregnancy and ...
The new clinic at 630 N. Last Chance Gulch, Suite 1100, Room 1111, will offer a full range of infusion and injection therapies in a comfortable environment.
The FDA has approved Kedrion Biopharma’s Qivigy, a 10% IV immunoglobulin therapy, for treating adults who have primary ...
"I realized there were a lot of other people across the country doing the same thing I was. So I figured I could connect with ...
YIMMUGO is now available in the United States through a limited distribution network that includes multiple specialty ...
Classical hematologist Srila Gopal, MD, tackles the unique complexities of treating and researching sickle cell disease and thalassemia.
QIVIGY is the realization of over 10 years of investments and internal efforts to bring a proprietary IVIG product from concept to commercialization FORT LEE, N.J., Sept. 29, 2025 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback